Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects

Pathophysiology

Volumn 21, Issue 1, 2014, Pages 95-104

  Yang, Jixin ^a,b   Su, Yanwei ^a,b   Zhou, Yu ^a,b   Besner, Gail E ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

HB EGF; Hemorrhagic shock; Intestinal injury; Ischemia and reperfusion; Necrotizing enterocolitis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROTECTION; CONTROLLED STUDY; HEMORRHAGIC SHOCK; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; INTESTINE ISCHEMIA; LYMPHOCYTE; MESENCHYMAL STEM CELL; MICROCIRCULATION; MOUSE; NECROTIZING ENTEROCOLITIS; NERVE CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RESUSCITATION; STEM CELL; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE DISTRIBUTION;

EID: 84896099820     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2013.11.008     Document Type: Article

References (94)

1. Kliegman R.M., Fanaroff A.A. Necrotizing enterocolitis. N. Engl. J. Med. 1984, 310:1093-1103.
2. Lee J.S., Polin R.A. Treatment and prevention of necrotizing enterocolitis. Semin. Neonatol. 2003, 8:449-459.
3. Caplan M.S., Jilling T. New concepts in necrotizing enterocolitis. Curr. Opin. Pediatr. 2001, 13:111-115.
4. Grave G.D., Nelson S.A., Walker W.A., Moss R.L., Dvorak B., Hamilton F.A., Higgins R., Raju T.N. New therapies and preventive approaches for necrotizing enterocolitis: report of a research planning workshop. Pediatr. Res. 2007, 62:510-514.
5. Besner G., Higashiyama S., Klagsbrun M. Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell. Regul. 1990, 1:811-819.
6. Higashiyama S., Abraham J.A., Miller J., Fiddes J.C., Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251:936-939.
7. Higashiyama S., Lau K., Besner G.E., Abraham J.A., Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J. Biol. Chem. 1992, 267:6205-6212.
8. Junttila T.T., Sundvall M., Maatta J.A., Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc. Med. 2000, 10:304-310.
9. Nishi E., Prat A., Hospital V., Elenius K., Klagsbrun M. N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO J. 2001, 20:3342-3350.
10. Shishido Y., Sharma K.D., Higashiyama S., Klagsbrun M., Mekada E. Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor. J. Biol. Chem. 1995, 270:29578-29585.
11. Altman K.A. Superior mesenteric artery occlusion. A review and case report. Am. J. Gastroenterol. 1971, 55:152-157.
12. Feng J., El-Assal O.N., Besner G.E. Heparin-binding EGF-like growth factor (HB-EGF) and necrotizing enterocolitis. Semin. Pediatr. Surg. 2005, 14:167-174.
13. Xia G., Martin A.E., Michalsky M.P., Besner G.E. Heparin-binding EGF-like growth factor preserves crypt cell proliferation and decreases bacterial translocation after intestinal ischemia/reperfusion injury. J. Pediatr. Surg. 2002, 37:1081-1087. discussion 1081-1087.
14. El-Assal O.N., Radulescu A., Besner G.E. Heparin-binding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation. Surgery 2007, 142:234-242.
15. Takashima S., Hori M. HB-EGF therapy for chronic heart failure. Nihon Rinsho 2007, 65(Suppl. 5):588-593.
16. Tanaka N., Sasahara M., Ohno M., Higashiyama S., Hayase Y., Shimada M. Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury. Brain Res. 1999, 827:130-138.
17. Nguyen H.T., Bride S.H., Badawy A.B., Adam R.M., Lin J., Orsola A., Guthrie P.D., Freeman M.R., Peters C.A. Heparin-binding EGF-like growth factor is up-regulated in the obstructed kidney in a cell- and region-specific manner and acts to inhibit apoptosis. Am. J. Pathol. 2000, 156:889-898.
18. El-Assal O.N., Besner G.E. Heparin-binding epidermal growth factor-like growth factor and intestinal ischemia-reperfusion injury. Semin. Pediatr. Surg. 2004, 13:2-10.
19. Christensen R.D., Gordon P.V., Besner G.E. Can we cut the incidence of necrotizing enterocolitis in half-today?. Fetal Pediatr. Pathol. 2010, 29:185-198.
20. Feng J., El-Assal O.N., Besner G.E. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J. Pediatr. Surg. 2006, 41:742-747. discussion 742-747.
21. Feng J., El-Assal O.N., Besner G.E. Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J. Pediatr. Surg. 2006, 41:144-149. discussion 144-149.
22. Yu X., Radulescu A., Zorko N., Besner G.E. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology 2009, 137:221-230.
23. Feng J., Besner G.E. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J. Pediatr. Surg. 2007, 42:214-220.
24. Radulescu A., Yu X., Orvets N.D., Chen Y., Zhang H.Y., Besner G.E. Deletion of the heparin-binding epidermal growth factor-like growth factor gene increases susceptibility to necrotizing enterocolitis. J. Pediatr. Surg. 2010, 45:729-734.
25. Radulescu A., Zhang H.Y., Yu X., Olson J.K., Darbyshire A.K., Chen Y., Besner G.E. Heparin-binding epidermal growth factor-like growth factor overexpression in transgenic mice increases resistance to necrotizing enterocolitis. J. Pediatr. Surg. 2010, 45:1933-1939.
26. Brandt L.J., Boley S.J. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 2000, 118:954-968.
27. Noda T., Iwakiri R., Fujimoto K., Matsuo S., Aw T.Y. Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. Am. J. Physiol. 1998, 274:G270-G276.
28. Parks D.A., Granger D.N. Contributions of ischemia and reperfusion to mucosal lesion formation. Am. J. Physiol. 1986, 250:G749-G753.
29. Xia G., Rachfal A.W., Martin A.E., Besner G.E. Upregulation of endogenous heparin-binding EGF-like growth factor (HB-EGF) expression after intestinal ischemia/reperfusion injury. J. Invest. Surg. 2003, 16:57-63.
30. Pillai S.B., Luquette M.H., Nowicki P.T., Besner G.E. Segmental intestinal ischemia: an improved method of producing small bowel injury. J. Invest. Surg. 1998, 11:123-128.
31. El-Assal O.N., Paddock H., Marquez A., Besner G.E. Heparin-binding epidermal growth factor-like growth factor gene disruption is associated with delayed intestinal restitution, impaired angiogenesis, and poor survival after intestinal ischemia in mice. J. Pediatr. Surg. 2008, 43:1182-1190.
32. Yu X., Radulescu A., Chen C.L., James I.O., Besner G.E. Heparin-binding EGF-like growth factor protects pericytes from injury. J. Surg. Res. 2012, 172:165-176.
33. Marik P.E. Total splanchnic resuscitation, SIRS, and MODS. Crit. Care Med. 1999, 27:257-258.
34. Chiara O., Pelosi P., Segala M., Turconi M.G., Brazzi L., Bottino N., Taccone P., Zambelli M., Tiberio G., Boswell S., Scalea T.M. Mesenteric and renal oxygen transport during hemorrhage and reperfusion: evaluation of optimal goals for resuscitation. J. Trauma 2001, 51:356-362.
35. Porter J.M., Ivatury R.R. In search of the optimal end points of resuscitation in trauma patients: a review. J. Trauma 1998, 44:908-914.
36. Zhang H.Y., Radulescu A., Chen C.L., Olson J.K., Darbyshire A.K., Besner G.E. Mice overexpressing the gene for heparin-binding epidermal growth factor-like growth factor (HB-EGF) have increased resistance to hemorrhagic shock and resuscitation. Surgery 2011, 149:276-283.
37. Zhang H.Y., Radulescu A., Chen Y., Besner G.E. HB-EGF improves intestinal microcirculation after hemorrhagic shock. J. Surg. Res. 2011, 171:218-225.
38. Michalsky M.P., Lara-Marquez M., Chun L., Besner G.E. Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk. J. Pediatr. Surg. 2002, 37:1-6.
39. Martin A.E., Luquette M.H., Besner G.E. Timing, route, and dose of administration of heparin-binding epidermal growth factor-like growth factor in protection against intestinal ischemia-reperfusion injury. J. Pediatr. Surg. 2005, 40:1741-1747.
40. Radulescu A., Zorko N.A., Yu X., Besner G.E. Preclinical neonatal rat studies of heparin-binding EGF-like growth factor in protection of the intestines from necrotizing enterocolitis. Pediatr. Res. 2009, 65:437-442.
41. Feng J., Mehta V.B., El-Assal O.N., Wu D., Besner G.E. Tissue distribution and plasma clearance of heparin-binding EGF-like growth factor (HB-EGF) in adult and newborn rats. Peptides 2006, 27:1589-1596.
42. Simon T.C., Gordon J.I. Intestinal epithelial cell differentiation: new insights from mice, flies and nematodes. Curr. Opin. Genet. Dev. 1995, 5:577-586.
43. Mitic L.L., Anderson J.M. Molecular architecture of tight junctions. Annu. Rev. Physiol. 1998, 60:121-142.
44. Potten C.S. Epithelial cell growth and differentiation. II. Intestinal apoptosis. Am. J. Physiol. 1997, 273:G253-G257.
45. Blikslager A.T., Moeser A.J., Gookin J.L., Jones S.L., Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 2007, 87:545-564.
46. Pillai S.B., Turman M.A., Besner G.E. Heparin-binding EGF-like growth factor is cytoprotective for intestinal epithelial cells exposed to hypoxia. J. Pediatr. Surg. 1998, 33:973-978. discussion 978-979.
47. El-Assal O.N., Besner G.E. HB-EGF enhances restitution after intestinal ischemia/reperfusion via PI3K/Akt and MEK/ERK1/2 activation. Gastroenterology 2005, 129:609-625.
48. Michalsky M.P., Kuhn A., Mehta V., Besner G.E. Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells in vitro. J. Pediatr. Surg. 2001, 36:1130-1135.
49. Zhang H.Y., Radulescu A., Besner G.E. Heparin-binding epidermal growth factor-like growth factor is essential for preservation of gut barrier function after hemorrhagic shock and resuscitation in mice. Surgery 2009, 146:334-339.
50. Kuhn M.A., Xia G., Mehta V.B., Glenn S., Michalsky M.P., Besner G.E. Heparin-binding EGF-like growth factor (HB-EGF) decreases oxygen free radical production in vitro and in vivo. Antioxid. Redox Signal. 2002, 4:639-646.
51. Huttenlocher A., Horwitz A.R. Integrins in cell migration. Cold Spring Harb. Perspect. Biol. 2011, 3:a005074.
52. Su Y., Yang J., Besner G.E. HB-EGF promotes intestinal restitution by affecting integrin-extracellular matrix interactions and intercellular adhesions. Growth Factors 2013, 31:39-55.
53. Barker N., Clevers H. Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 2007, 133:1755-1760.
54. Clatworthy J.P., Subramanian V. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mech. Dev. 2001, 101:3-9.
55. Potten C.S., Gandara R., Mahida Y.R., Loeffler M., Wright N.A. The stem cells of small intestinal crypts: where are they?. Cell Prolif. 2009, 42:731-750.
56. Markel T.A., Crisostomo P.R., Lahm T., Novotny N.M., Rescorla F.J., Tector J., Meldrum D.R. Stem cells as a potential future treatment of pediatric intestinal disorders. J. Pediatr. Surg. 2008, 43:1953-1963.
57. Barker N., van de Wetering M., Clevers H. The intestinal stem cell. Genes Dev. 2008, 22:1856-1864.
58. Chen C.L., Yu X., James I.O., Zhang H.Y., Yang J., Radulescu A., Zhou Y., Besner G.E. Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis. Lab. Invest. 2012, 92:331-344.
59. Yang J., Watkins D., Chen C.L., Zhang H.Y., Zhou Y., Velten M., Besner G.E. A technique for systemic mesenchymal stem cell transplantation in newborn rat pups. J. Invest. Surg. 2012, 25:405-414.
60. Yang J., Watkins D., Chen C.L., Bhushan B., Zhou Y., Besner G.E. Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis. J. Am. Coll. Surg. 2012, 215:534-545.
61. Weil B.R., Markel T.A., Herrmann J.L., Abarbanell A.M., Meldrum D.R. Mesenchymal stem cells enhance the viability and proliferation of human fetal intestinal epithelial cells following hypoxic injury via paracrine mechanisms. Surgery 2009, 146:190-197.
62. Mowat A.M., Viney J.L. The anatomical basis of intestinal immunity. Immunol. Rev. 1997, 156:145-166.
63. Grotz M., Regel G., Schratt H.E., Seekamp A., Pape H.C., Tscherne H. Intestinal cytokine liberation after intestinal ischemia in the rat - studies in the Ussing chamber system. Z. Gastroenterol. 1996, 34:783-790.
64. Xia G., Martin A.E., Besner G.E. Heparin-binding EGF-like growth factor downregulates expression of adhesion molecules and infiltration of inflammatory cells after intestinal ischemia/reperfusion injury. J. Pediatr. Surg. 2003, 38:434-439.
65. Rocourt D.V., Mehta V.B., Besner G.E. Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury. J. Surg. Res. 2007, 139:269-273.
66. Rocourt D.V., Mehta V.B., Wu D., Besner G.E. Heparin-binding EGF-like growth factor decreases neutrophil-endothelial cell interactions. J. Surg. Res. 2007, 141:262-266.
67. Zhang H.Y., James I., Chen C.L., Besner G.E. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) preserves gut barrier function by blocking neutrophil-endothelial cell adhesion after hemorrhagic shock and resuscitation in mice. Surgery 2012, 151:594-605.
68. Lee J.J., Boulanger C.M., Kirchengast M., Vanhoutte P.M. Trandolapril plus verapamil inhibits the coronary vasospasm induced by hypoxia following ischemia-reperfusion injury in dogs. Gen. Pharmacol. 1996, 27:1057-1059.
69. Park W.M., Gloviczki P., Cherry K.J., Hallett J.W., Bower T.C., Panneton J.M., Schleck C., Ilstrup D., Harmsen W.S., Noel A.A. Contemporary management of acute mesenteric ischemia: factors associated with survival. J. Vasc. Surg. 2002, 35:445-452.
70. Zhou Y., Brigstock D., Besner G.E. Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles. Microvasc. Res. 2009, 78:78-85.
71. Mehta V.B., Besner G.E. HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors 2007, 25:253-263.
72. Mehta V.B., Zhou Y., Radulescu A., Besner G.E. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors 2008, 26:301-315.
73. Radulescu A., Zhang H.Y., Chen C.L., Chen Y., Zhou Y., Yu X., Otabor I., Olson J.K., Besner G.E. Heparin-binding EGF-like growth factor promotes intestinal anastomotic healing. J. Surg. Res. 2011, 171:540-550.
74. Hirschi K.K., D'Amore P.A Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32:687-698.
75. Barlow A.J., Wallace A.S., Thapar N., Burns A.J. Critical numbers of neural crest cells are required in the pathways from the neural tube to the foregut to ensure complete enteric nervous system formation. Development 2008, 135:1681-1691.
76. Jin K., Sun Y., Xie L., Childs J., Mao X.O., Greenberg D.A. Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 2004, 24:399-408.
77. Zhou Y., Besner G.E. Heparin-binding epidermal growth factor-like growth factor is a potent neurotrophic factor for PC12 cells. Neurosignals 2010, 18:141-151.
78. Forstermann U. Biochemistry and molecular biology of nitric oxide synthases. Arzneimittelforschung 1994, 44:402-407.
79. Salzman A.L. Nitric oxide in the gut. New Horiz. 1995, 3:352-364.
80. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271:C1424-C1437.
81. Miller M.J., Sandoval M. Nitric Oxide. III. A molecular prelude to intestinal inflammation. Am. J. Physiol. 1999, 276:G795-G799.
82. Xia G., Lara-Marquez M., Luquette M.H., Glenn S., Haque A., Besner G.E. Heparin-binding EGF-like growth factor decreases inducible nitric oxide synthase and nitric oxide production after intestinal ischemia/reperfusion injury. Antioxid. Redox Signal. 2001, 3:919-930.
83. Lara-Marquez M.L., Mehta V., Michalsky M.P., Fleming J.B., Besner G.E. Heparin-binding EGF-like growth factor down regulates proinflammatory cytokine-induced nitric oxide and inducible nitric oxide synthase production in intestinal epithelial cells. Nitric Oxide 2002, 6:142-152.
84. Mehta V.B., Besner G.E. Inhibition of NF-kappa B activation and its target genes by heparin-binding epidermal growth factor-like growth factor. J. Immunol. 2003, 171:6014-6022.
85. Mehta V.B., Besner G.E. Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-kappa B activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2005, 175:1911-1918.
86. Nankervis C.A., Dunaway D.J., Nowicki P.T. Determinants of terminal mesenteric artery resistance during the first postnatal month. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G678-G686.
87. Nowicki P.T., Caniano D.A., Hammond S., Giannone P.J., Besner G.E., Reber K.M., Nankervis C.A. Endothelial nitric oxide synthase in human intestine resected for necrotizing enterocolitis. J. Pediatr. 2007, 150:40-45.
88. Southan G.J., Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 1996, 51:383-394.
89. Deitch E.A. Multiple organ failure. Pathophysiology and potential future therapy. Ann. Surg. 1992, 216:117-134.
90. Rotstein O.D. Pathogenesis of multiple organ dysfunction syndrome: gut origin, protection, and decontamination. Surg. Infect. (Larchmt) 2000, 1:217-223. discussion 223-215.
91. Fink M.P., Delude R.L. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit. Care Clin. 2005, 21:177-196.
92. Hotchkiss R.S., Swanson P.E., Freeman B.D., Tinsley K.W., Cobb J.P., Matuschak G.M., Buchman T.G., Karl I.E. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 1999, 27:1230-1251.
93. James I.A., Chen C.L., Huang G., Zhang H.Y., Velten M., Besner G.E. HB-EGF protects the lungs after intestinal ischemia/reperfusion injury. J. Surg. Res. 2010, 163:86-95.
94. Chen C.L., Mehta V.B., Zhang H.Y., Wu D., Otabor I., Radulescu A., El-Assal O.N., Feng J., Chen Y., Besner G.E. Intestinal phenotype in mice overexpressing a heparin-binding EGF-like growth factor transgene in enterocytes. Growth Factors 2010, 28:82-97.